Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device Platform Technologies

Animas Corp.

This article was originally published in Start Up

Executive Summary

Animas's Corp. ambition is the development of an insulin infusion pump and an implantable optical glucose sensor for insulin-dependent diabetes.

You may also be interested in...



Cracking Open the IPO Window for Pre-Commercial Device Companies

DexCom's is a bellwether IPO: if it holds its value, it could open the door for other pre-commercial device businesses. If it doesn't, it could keep it shut-as it's been since the class of 1995-96 device companies disappointed investors by missing their commercial targets.

Cracking Open the IPO Window for Pre-Commercial Device Companies

DexCom's is a bellwether IPO: if it holds its value, it could open the door for other pre-commercial device businesses. If it doesn't, it could keep it shut-as it's been since the class of 1995-96 device companies disappointed investors by missing their commercial targets.

Cracking Open the IPO Window for Pre-Commercial Device Companies

DexCom's is a bellwether IPO: if it holds its value, it could open the door for other pre-commercial device businesses. If it doesn't, it could keep it shut-as it's been since the class of 1995-96 device companies disappointed investors by missing their commercial targets.

Table

View full table

Topics

Related Companies

Tags:
Medical Device Platform Technologies
Latest Headlines

Intarcia’s Implantable GLP-1 Gets Unanimous No Vote But Lots Of New Trial Design Advice

Class I Recall For Medline’s Saline Solution Packs

News We're Watching: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients

Getting Personal With Tom Miller: CEO Turned VC On Ethical Bets In Diagnostics

See All
UsernamePublicRestriction

Register

MT036970

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By